The invention belongs to the technical field of tumor molecular biology, in particular to the application of circARHGAP12 in the preparation of nasopharyngeal cancer therapeutic preparations and therapeutic preparations. For the first time, we found that circARHGAP12 may be a potential target for nasopharyngeal carcinoma treatment. Because siRNA has good silencing effect, the invention uses siRNA to interfere with circARHGAP12 by designing the splicing sites at the head-tail junction of circular RNA. Scratch healing experiments and matrix gel invasion experiments are carried out in nasopharyngeal carcinoma cell lines HONE1, HNE2 and CNE2. Compared with the control group, the invasion and migration ability of cells in the circARHGAP12 group knocked down by siRNA is significantly weakened, that is, the silencing of circARHGAP12 cells. Inhibition of invasion and metastasis of nasopharyngeal carcinoma cells. It shows that inhibiting circARHGAP12 can treat nasopharyngeal carcinoma, which has far-reaching clinical significance and important application prospects.
【技术实现步骤摘要】
circARHGAP12在制备鼻咽癌治疗制剂中的应用和治疗制剂
本专利技术属于肿瘤分子生物学
,具体涉及一种抑制环状RNAcircARHGAP12表达的试剂及其在制备鼻咽癌治疗制剂中的应用。
技术介绍
鼻咽癌(Nasopharyngealcarcinoma,NPC)是一种高转移的恶性肿瘤,具有不同的发病机制和组织病理学表现。遗传易感性,表观遗传,种族衍生,地理分布,环境因素和EBV病毒感染导致NPC的恶性。鼻咽癌的发生有明显的区域特征,东南亚特别是华南和北非的病例占多数。NPC的治疗策略主要是放疗辅以化疗。虽然早期NPC患者的5年总生存率高达95%,但鼻咽和颈淋巴结复发率为8.6%~23.7%。这是由于NPC的发生和发展涉及复杂的基因调控和多阶段过程,其分子机制尚不清楚,加之肿瘤异质性和放疗抵抗引起的个体差异,传统放疗的治疗效果不是非常的理想。因此,研究治疗鼻咽癌的治疗靶标和诊断的分子标记物至关重要。环状RNA(CircularRNA)主要来源于蛋白质编码基因的外显子区,也可以由内含子区、UTR区、基因间区、非编码RNA位点及已知转录物的反义位点形成。CircRNA是由前体mRNA(precursormessengerRNA,pre-mRNA)反向拼接而形成的一类不具有5‘末端帽子和3’末端poly(A)尾巴并以共价键形成环状套索结构的非编码RNA分子。CircRNA形成过程可以分为两大类,即外显子环化(exoncircularization)和内含子环化(introncircularization)两大机制。Jeck等提出外显子来源的circRNA ...
【技术保护点】
1.抑制环状RNA circARHGAP12表达的试剂在制备治疗鼻咽癌制剂中的应用,所述的环状RNA circARHGAP12序列如SEQ ID NO.1所示。
【技术特征摘要】
1.抑制环状RNAcircARHGAP12表达的试剂在制备治疗鼻咽癌制剂中的应用,所述的环状RNAcircARHGAP12序列如SEQIDNO.1所示。2.根据权利要求1所述的应用,其特征在于,所述的抑制环状RNAcircARHGAP12表达的试剂包括siRNA。3.根据权利要求2所述的应用,其特征在于,所述的siRNA如下:正义链(5'-3')UGAACAGAUAAGGGUUUAAUU反义链(5'-3')UUAAACCCUUAUCUGUUCAUU。4.根据权利要求2所述的应用,其特征在于,所述的抑制circARHGAP12表达的试剂还包括阴性对照:正义链(5'-3')UGAACAGAUAUGAGCAUCGUU反义链(5'-3')CGAUGCUCAUAUCUGUUCAUU。5.一种治疗鼻咽癌的制...
【专利技术属性】
技术研发人员:熊芳,曾朝阳,郭灿,熊炜,范春梅,莫勇真,王裕民,邓湘赢,张文玲,向波,李小玲,李桂源,
申请(专利权)人:中南大学,
类型:发明
国别省市:湖南,43
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。